Articles related to NEOADJUVANT TREATMENT

Dr. Rita Rao shares her expert perspective on the goals of neoadjuvant therapy, treatment selection, and the evolving landscape of HER2-targeted strategies.

Comprehensive genetic profiling now plays a central role in ovarian cancer management, with mandatory offering of both germline and somatic testing for all patients at diagnosis.

The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.

In the realm of HER2-positive early breast cancer, achieving a pathological complete response (pCR) post-neoadjuvant therapy has been linked to a markedly reduced risk of recurrence, highlighting the critical role of tailored treatment strategies in improving patient outcomes.

Highlighting a paradigm shift in breast cancer treatment, the NRG Oncology/NSABP B-51/RTOG 1304 study demonstrates that certain patients with node-negative breast cancer post-neoadjuvant chemotherapy may safely omit adjuvant regional nodal irradiation, challenging conventional treatment approaches and potentially improving patient quality of life.

Discover how pre-surgery treatment with T-VEC can significantly improve long-term survival rates in advanced melanoma patients, as revealed in a recent phase 2 trial.